Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Company Performance - Astrazeneca's stock closed at $85.31, reflecting a +1.98% change from the previous day's closing price, outperforming the S&P 500 which gained 0.01% [1] - Over the past month, Astrazeneca shares have increased by 2.29%, which is below the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1] Earnings Projections - The upcoming EPS for Astrazeneca is projected at $1.14, indicating a 9.62% increase compared to the same quarter of the previous year [2] - Revenue is expected to reach $14.86 billion, representing a 9.57% increase compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $4.58 per share and revenue at $58.6 billion, reflecting changes of +11.44% and +8.37% respectively from the previous year [3] - Recent changes to analyst estimates suggest a positive outlook for Astrazeneca's business trends [3] Valuation Metrics - Astrazeneca has a Forward P/E ratio of 18.26, which is lower than the industry average of 19.42 [6] - The company has a PEG ratio of 1.54, compared to the industry average PEG ratio of 1.82 [6] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Astrazeneca, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - The top 50% rated industries are shown to outperform the bottom half by a factor of 2 to 1 [7]